Evidence map›Paper›PMID 40898305›Full record

ArticleJournal of intensive care2025

Plasma endostatin and its association with new-onset acute kidney injury in critical care.

Hazem Koozi, Jonas Engström, Anders Larsson, Martin Spångfors, Hans Friberg, Attila Frigyesi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hazem KooziDepartment of Clinical Sciences, Anaesthesiology and Intensive Care, Lund University, SE-22185, Lund, Sweden. hazem.koozi@med.lu.se.
Jonas EngströmDepartment of Clinical Sciences, Anaesthesiology and Intensive Care, Lund University, SE-22185, Lund, Sweden.
Anders LarssonDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, SE-75185, Uppsala, Sweden.
Martin SpångforsDepartment of Clinical Sciences, Anaesthesiology and Intensive Care, Lund University, SE-22185, Lund, Sweden.
Hans FribergDepartment of Clinical Sciences, Anaesthesiology and Intensive Care, Lund University, SE-22185, Lund, Sweden.
Attila FrigyesiDepartment of Clinical Sciences, Anaesthesiology and Intensive Care, Lund University, SE-22185, Lund, Sweden.

Funding

Crafoordska Stiftelsen 2021-0833Governmental funding of clinical research within the Swedish National Health Service (ALF) 2022:YF0009 and 2022-0075Government funding of clinical research within the Swedish National Health Service (ALF) 2022-0226Regional research support, Region Skåne 2022-1284Swedish Heart and Lung Foundation 2021-10233Swedish Heart and Lung Foundation (HLF) 2022-0352 and 2022-0458
6 · The paper itself

Abstract

backgroundEndostatin is a promising biomarker for predicting acute kidney injury (AKI) and mortality in the intensive care unit (ICU). We investigated plasma endostatin levels at ICU admission as predictors of new-onset AKI within 48 h after ICU admission, renal replacement therapy (RRT) within 7 days after ICU admission, and 30-day mortality.

methodsA retrospective multicentre study was performed with admissions to four ICUs. Blood samples were prospectively obtained at ICU admission and retrospectively analysed. The Kidney Disease: Improving Global Outcomes (KDIGO) criteria defined AKI. Endostatin at ICU admission was compared to and adjusted for creatinine, cystatin C, and the Simplified Acute Physiology Score 3 (SAPS-3). Regression models and mean areas under the receiver operating characteristic curves (AUCs) from repeated cross-validation were assessed.

resultsIn total, 4732 admissions were included. Endostatin was associated with new-onset AKI (OR 1.7, 95% CI 1.5

conclusionsEndostatin at ICU admission is an independent predictor of new-onset AKI and may improve early AKI risk assessment in the ICU. However, its predictive value for RRT and 30-day mortality appears limited. External validation and studies on its clinical utility are warranted.

Indexed as

Acute kidney injuryCritical careEndostatinIntensive careMortality.Renal replacement therapy

Identifiers

PMID40898305
PMCPMC12403487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.